Pricing Log in Create free account

Altimmune, Inc. (ALT) vs Contineum Therapeutics, Inc. (CTNM)

Altimmune, Inc. and Contineum Therapeutics, Inc. are both Biotechnology companies. Altimmune, Inc. and Contineum Therapeutics, Inc. are of similar size ($507.7M and $503.4M). Across the 10 metrics below, Altimmune, Inc. leads on 6 and Contineum Therapeutics, Inc. on 4.

Valuation

Metric ALT CTNM Biotechnology median
P/E n/m n/m 8.56
P/S 10,320.35 n/m 10.17
P/B 1.00 1.37 2.34
Price to free cash flow n/m n/m 20.42
EV/EBITDA n/m n/m 0.69
EV/Sales 3,985.41 n/m 9.64
Earnings yield (30.47%) (19.75%) (29.41%)
Free cash flow yield (16.17%) (16.29%) (23.50%)

Profitability

Metric ALT CTNM Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (28.87%) (28.01%) (56.66%)
Return on assets (25.58%) (26.57%) (49.22%)
Return on invested capital (34.30%) (1,334.41%) 0.00%

Growth

Metric ALT CTNM Biotechnology median
Revenue growth (TTM) 130.00% — 5.64%
EPS growth (last fiscal year) 25.37% 0.46% 30.08%
Revenue growth, 5-year CAGR (65.33%) — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ALT CTNM Biotechnology median
Debt to equity 0.07 0.00 0.00
Current ratio 26.78 37.17 4.72
Net debt to EBITDA 2.49 3.88 0.96

Dividend

Metric ALT CTNM Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric ALT CTNM Biotechnology median
Market cap 507.69m 503.37m 151.40m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack